Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease

Mol Cell Biochem. 2006 Mar;284(1-2):175-82. doi: 10.1007/s11010-005-9047-9.


Background: We reported that urinary L-FABP reflected the progression of chronic kidney disease (CKD). This study is aimed to evaluate the clinical significance of urinary liver type fatty acid binding protein (L-FABP) as a biomarker for monitoring CKD.

Methods: Urinary L-FABP was measured using human L-FABP ELISA kit (CMIC.Co., Ltd., Tokyo, Japan). The relations between urinary L-FABP and clinical parameters were evaluated in non-diabetic CKD (n = 48) for a year. In order to evaluate the influence of serum L-FABP derived from liver upon urinary L-FABP, both serum and urinary L-FABP were simultaneously measured in patients with CKD (n = 73).

Results: For monitoring CKD, the cut-off value in urinary L-FABP was determined as 17.4 microg/g.cr. by using a receiver operating characteristics (ROC) curve. Renal function deteriorated significantly more in patients with 'high' urinary L-FABP (n = 36) than in those with 'low' L-FABP (n = 12). The decrease in creatinine clearance was accompanied by an increase in urinary L-FABP, but not in urinary protein. Serum L-FABP in patients with CKD was not correlated with urinary L-FABP.

Conclusion: Urinary excretion of L-FABP increases with the deterioration of renal function. Serum L-FABP did not influence on urinary L-FABP. Urinary L-FABP may be a useful clinical biomarker for monitoring CKD.

MeSH terms

  • Adult
  • Aged
  • Biomarkers / blood
  • Biomarkers / urine
  • Enzyme-Linked Immunosorbent Assay
  • Fatty Acid-Binding Proteins / blood*
  • Fatty Acid-Binding Proteins / urine*
  • Female
  • Humans
  • Kidney Failure, Chronic / diagnosis*
  • Liver / metabolism
  • Male
  • Middle Aged


  • Biomarkers
  • FABP1 protein, human
  • Fatty Acid-Binding Proteins